ArticleCureus2026
A Dual Response to CD20xCD3 Bispecific Therapy: Remission of Relapsed Diffuse Large B-cell Lymphoma and Improvement in Immune Thrombocytopenia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia (ITP) is an autoimmune cytopenia that may occur in association with lymphoproliferative disorders. In such cases, treatment of the underlying malignancy may influence platelet recovery. CD20xCD3 bispecific antibodies have become important options for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but their effect on coexisting autoimmune cytopenias is not well defined. We report the case of an 81-year-old woman with relapsed DLBCL arising from an underlying marginal zone lymphoma and longstanding ITP. She achieved complete metabolic remission with initial rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (R-CHOP) and again with polatuzumab vedotin, bendamustine, and rituximab (Pola-BR) after the first relapse, but her thrombocytopenia persisted. Following a second relapse, she was treated with epcoritamab, a CD20xCD3 bispecific T-cell engager. Her course was complicated by steroid-induced hyperglycemia, grade 1 cytokine release syndrome, and adrenal insufficiency, but she achieved complete metabolic remission on follow-up positron emission tomography. Her platelet counts also markedly improved, increased to 142 K/mcL (140-450 K/mcL) from a chronically thrombocytopenic baseline. This case highlights the possibility that bispecific therapy may simultaneously control relapsed DLBCL and secondary ITP through depletion of pathogenic CD20-expression B cells, as well as exhaustion and redirection of T-cells. Further study is needed to determine whether this represents a reproducible therapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.